Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pliant Therapeutics (PLRX) Invested Capital (2019 - 2025)

Historic Invested Capital for Pliant Therapeutics (PLRX) over the last 7 years, with Q3 2025 value amounting to $230.7 million.

  • Pliant Therapeutics' Invested Capital fell 3862.53% to $230.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $230.7 million, marking a year-over-year decrease of 3862.53%. This contributed to the annual value of $334.3 million for FY2024, which is 3087.86% down from last year.
  • According to the latest figures from Q3 2025, Pliant Therapeutics' Invested Capital is $230.7 million, which was down 3862.53% from $250.4 million recorded in Q2 2025.
  • Over the past 5 years, Pliant Therapeutics' Invested Capital peaked at $571.9 million during Q1 2023, and registered a low of $157.7 million during Q2 2022.
  • Moreover, its 5-year median value for Invested Capital was $323.3 million (2022), whereas its average is $337.4 million.
  • In the last 5 years, Pliant Therapeutics' Invested Capital soared by 24444.78% in 2023 and then tumbled by 4075.86% in 2025.
  • Quarter analysis of 5 years shows Pliant Therapeutics' Invested Capital stood at $199.1 million in 2021, then soared by 62.4% to $323.3 million in 2022, then soared by 49.61% to $483.6 million in 2023, then tumbled by 30.88% to $334.3 million in 2024, then tumbled by 30.98% to $230.7 million in 2025.
  • Its Invested Capital was $230.7 million in Q3 2025, compared to $250.4 million in Q2 2025 and $287.4 million in Q1 2025.